OKYO Pharma is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases.
| Website | https://www.okyopharma.com/ |
| Ticker | OKYO |
| Revenue | $9 million |
| Employees | 11 (9 on RocketReach) |
| Founded | 2018 |
| Phone | +44 20 7495 2379 |
| Industry | Biotechnology Research, Drug Manufacturing & Research, Pharmaceuticals, Healthcare |
| Keywords | Dry Eye Treatment, Receptor Targeting, Ophthalmic Therapeutics, Ocular Inflammation, Eye Disease Treatment, Drug Discovery, Pharmaceutical Research, Ophthalmology, Ocular Drug Delivery, Biotechnology, Clinical Trials |
| Competitors | Roche, Novartis, Pfizer, Sanofi, AstraZeneca, Bristol Myers Squibb, Amgen, Regeneron, Gilead Sciences, Lilly India +47 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies |
Looking for a particular OKYO Pharma employee's phone or email?
OKYO Pharma Questions
The OKYO Pharma annual revenue was $9 million in 2026.
Robert Dempsey is the CEO of OKYO Pharma.
9 people are employed at OKYO Pharma.
The NAICS codes for OKYO Pharma are [32541, 325, 32, 3254].
The SIC codes for OKYO Pharma are [283, 28].
Top OKYO Pharma Employees
-
Robert Dempsey
Chief Executive Officer at OKYO Pharma
Boston, MA, US45+ -
Raj Patil
Chief Scientific Officer at OKYO Pharma
New York, NY, US25+ -
Gary Jacob
Chief Development Officer at OKYO Pharma
New York, NY, US11 -
Kristie Veasey
Executive Director, Clinical Development at OKYO Pharma
Wake Forest, NC, US25 -
Bernard Denoyer
Independent Non-Executive Director at OKYO Pharma
Connecticut, United States25+ -
Afshin Fcca
Finance Manager at OKYO Pharma
London, England, GB1 -
Linda M
Strategic Partner at OKYO Pharma
United States
Related Companies
G2Crowd Trusted
300K+
Plugin Users
